Wisconsin Department of Safety and Professional Services
Division of Policy Development
4822 Madison Yards Way
PO Box 8366
Madison WI 53708-8366

Phone: 608-266-2112
Web: http://dsps.wi.gov
Email: dsps@wisconsin.gov

Tony Evers, Governor
Dan Hereth, Secretary

VIRTUAL/TELECONFERENCE
CONTROLLED SUBSTANCES BOARD
Virtual, 4822 Madison Yards Way, Madison
Contact: Tom Ryan (608) 266-2112
September 19, 2025

The following agenda describes the issues that the Board plans to consider at the meeting. At the time of the meeting, items may be removed from the agenda. Please consult the meeting minutes for a description of the actions and deliberations of the Board.

AGENDA

10:00 A.M.

OPEN SESSION – CALL TO ORDER – ROLL CALL

A. **Adoption of Agenda (1-3)**

B. **Approval of Minutes July 11, 2025 (4-5)**

C. Reminders: Conflicts of Interests, Scheduling Concerns

D. Introductions, Announcements and Recognition

E. Administrative Matters – Discussion and Consideration
   1) Department, Staff, and Board Updates
   2) Board Members – Term Expiration Dates
      a. Barman, Subhadeep – 5/1/2019
      b. Bellay, Yvonne – DATCP Representative
      c. Bloom, Alan – 5/1/2020
      d. Eberhardy, Cullen – AG Representative
      e. Englebert, Doug – DHS Representative
      f. Gundersen, David – Dentistry Examining Board Representative
      g. Kane, Amanda – Board of Nursing Representative
      h. Majeed-Haqqi, Lubna – Medical Examining Board Representative
      i. Weitekamp, John – Pharmacy Examining Board Representative
   3) Alternates
      a. Alton, Troy – Dentistry Examining Board Representative
      b. Leuthner, Steven – Medical Examining Board Representative
      c. Weinman, Robert – Board of Nursing Representative

F. **10:00 A.M. PRELIMINARY PUBLIC HEARING ON STATEMENT OF SCOPE: SS 055-25 on CSB 2.012, Relating to Scheduling 7 Fentanyl-Related Substances (6-9)**
   1) Review Preliminary Hearing Comments

G. **Administrative Rule Matters – Discussion and Consideration (10-22)**
   1) Affirmative Action Order **(11-12)**
      a. CSB 2.013, Relating to Scheduling Dipentylone
      b. CSB 2.014, Relating to Scheduling 2 Synthetic Benzimidazole-Opioids
   2) Final Rule Draft and Legislative Report **(13-21)**
      a. 2.011, Scheduling Ethylphenidate
   3) Pending or Possible Rulemaking Projects **(22)**
      a. Rule Projects

H. **Prescription Drug Monitoring Program (PDMP) Updates – Discussion and Consideration (23-32)**
   1) WI ePDMP Operations
      a. Recent and Upcoming Releases
      b. EHR Integration Status
   2) WI PDMP Outreach

I. **DSPS Interdisciplinary Advisory Committee Liaison Report – Discussion and Consideration**
   1) Draft IV Hydration Guidance Document
   2) Future Topics

J. **Board Member Reports – Discussion and Consideration**
   1) Medical Examining Board
   2) Dentistry Examining Board
   3) Board of Nursing
   4) Pharmacy Examining Board

K. Report from the Referral Criteria Work Group – Discussion and Consideration

L. Liaison Reports

M. Speaking Engagements, Travel, or Public Relations Requests, and Reports

N. Deliberation on Special Use Authorizations – Discussion and Consideration

O. Discussion and Consideration of Items Received After Preparation of the Agenda
   1) Introductions, Announcements, and Recognition
   2) Administrative Matters
   3) Election of Officers
   4) Appointment of Liaisons and Alternates
   5) Delegation of Authorities
   6) Informational Items
   7) Division of Legal Services and Compliance (DLSC) Matters
   8) Education and Examination Matters
   9) Credentialing Matters
   10) Practice Matters
   11) Legislative and Administrative Rule Matters
   12) Liaison Reports
   13) Public Health Emergencies
   14) Appearances from Requests Received or Renewed

15) Speaking Engagements, Travel, or Public Relations Requests, and Reports
16) Consulting with Legal Counsel

P. **Public Comments**

CONVENE TO CLOSED SESSION to deliberate on cases following hearing (s. 19.85(1)(a), Stats.); to consider licensure or certification of individuals (s. 19.85(1)(b), Stats.); to consider individual histories or disciplinary data (s. 19.85(1)(f), Stats.); and to confer with legal counsel (s. 19.85(1)(g), Stats.).

Q. Deliberation on Special Use Authorizations – Discussion and Consideration

R. Consulting with Legal Counsel

RECONVENE TO OPEN SESSION IMMEDIATELY FOLLOWING CLOSED SESSION

S. Vote on Items Considered or Deliberated Upon in Closed Session if Voting is Appropriate

T. Open Session Items Noticed Above Not Completed in the Initial Open Session

ADJOURNMENT

NEXT MEETING: NOVEMBER 14, 2025

****

MEETINGS AND HEARINGS ARE OPEN TO THE PUBLIC, AND MAY BE CANCELLED WITHOUT NOTICE.

Times listed for meeting items are approximate and depend on the length of discussion and voting. All meetings are held virtually unless otherwise indicated. In-person meetings are typically conducted at 4822 Madison Yards Way, Madison, Wisconsin, unless an alternative location is listed on the meeting notice. In order to confirm a meeting or to request a complete copy of the board's agenda, please visit the Department website at https:\\dsps.wi.gov. The board may also consider materials or items filed after the transmission of this notice. Times listed for the commencement of any agenda item may be changed by the board for the convenience of the parties. The person credentialed by the board has the right to demand that the meeting at which final action may be taken against the credential be held in open session. Requests for interpreters for the hard of hearing, or other accommodations, are considered upon request by contacting the Affirmative Action Officer or reach the Meeting Staff by calling 608-267-7213.

VIRTUAL/TELECONFERENCE
CONTROLLED SUBSTANCES BOARD
MEETING MINUTES
JULY 11, 2025

PRESENT: Subhadeep Barman, Alan Bloom, Doug Englebert, David Gundersen, Amanda Kane, John Weitekamp

ABSENT: Yvonne Bellay, Cullen Eberhardy, Lubna Majeed-Haqqi

STAFF: Tom Ryan, Executive Director; Jameson Whitney, Legal Counsel; Nilajah Hardin, Administrative Rules Coordinator; Ashley Sarnosky, Board Administrative Specialist; and other DSPS Staff

CALL TO ORDER

Doug Englebert, Chairperson, called the meeting to order at 10:00 a.m. A quorum was confirmed with six (6) members present.

ADOPTION OF AGENDA

MOTION: Amanda Kane moved, seconded by David Gundersen, to adopt the Agenda as published. Motion carried unanimously.

APPROVAL OF MINUTES OF MAY 9, 2025

MOTION: Alan Bloom moved, seconded by John Weitekamp, to adopt the Minutes of May 9, 2025, as published. Motion carried unanimously.

ADMINISTRATIVE RULE MATTERS

Scope Statement:

CSB 2.012, Relating to Scheduling 7 Fentanyl-related Substances

MOTION: Subhadeep Barman moved, seconded by John Weitekamp, to approve the Scope Statement creating CSB 2.012, Relating to Scheduling 7 Fentanyl-related Substances, for submission to the Department of Administration and Governor's Office and for publication. Additionally, the Board authorizes the Chairperson to approve the Scope Statement for implementation no less than 10 days after publication. If the Board is directed to hold a preliminary public hearing on the Scope Statement, the Chairperson is authorized to approve the required notice of hearing. Motion carried unanimously.

Preliminary Rule Draft:

CSB 2.011, Relating to Scheduling Ethylphenidate

MOTION: Subhadeep Barman moved, seconded by Amanda Kane, to approve the preliminary rule draft of CSB 2.011, Relating to Scheduling Ethylphenidate, for posting for economic impact comments and submission to the Clearinghouse. Motion carried unanimously.

Adoption Order:

CSB 2.006, Relating to Scheduling 5 Synthetic Cannabinoids
CSB 2.007, Relating to Scheduling ADB-BUTINACA, α-PiHP, and 3-MMC
CSB 2.008, Relating to Scheduling 2-methyl AP-237

MOTION: John Weitekamp moved, seconded by Doug Englebert, to approve the Adoption Order for the following rules:
Clearinghouse Rule 24-083 (CSB 2.006), Relating to Scheduling 5 Synthetic Cannabinoids.
Clearinghouse Rule 24-084 (CSB 2.007), Relating to Scheduling ADB-BUTINACA, α-PiHP, and 3-MMC
Clearinghouse Rule 24-085 (CSB 2.008), Relating to Scheduling 2-methyl AP-237
Motion carried unanimously.

DSPS INTERDISCIPLINARY ADVISORY COMMITTEE LIAISON REPORT

Draft IV Hydration Guidance Document

MOTION: John Weitekamp moved, seconded by Amanda Kane, to delegate IAC Liaison the authority to approve the IV Hydration guidance on behalf of the Board. Motion carried unanimously.

ADJOURNMENT

MOTION: Alan Bloom moved, seconded by John Weitekamp, to adjourn the meeting. Motion carried unanimously.

The meeting adjourned at 10:46 a.m.

State of Wisconsin
Department of Safety & Professional Services

AGENDA REQUEST FORM

1) Name and title of person submitting the request:	2) Date when request submitted:
Nilajah Hardin **Administrative Rules Coordinator**	**09/08/25** Items will be considered late if submitted after 12:00 p.m. on the deadline date which is 8 business days before the meeting

3) Name of Board, Committee, Council, Sections:

Controlled Substances Board

4) Meeting Date:	5) Attachments:	6) How should the item be titled on the agenda page?
09/19/25	☒ Yes ☐ No	**10:00 A.M. Preliminary Hearing on Statement of Scope – SS 055-25 on CSB 2.012, Relating to Scheduling 7 Fentanyl-Related Substances** **1. Review Preliminary Hearing Comments**

7) Place Item in:	8) Is an appearance before the Board being scheduled? *(If yes, please complete Appearance Request for Non-DSPS Staff)*	9) Name of Case Advisor(s), if required:
☒ Open Session ☐ Closed Session	☐ Yes ☒ No	**N/A**

10) Describe the issue and action that should be addressed:

The Board will hold a Preliminary Hearing on this scope statement as directed by the Joint Committee for Review of Administrative Rules.

11) Authorization

Nilajah D. Hardin — 09/08/25

Signature of person making this request — **Date**

Supervisor (if required) — **Date**

Executive Director signature (indicates approval to add post agenda deadline item to agenda) — **Date**

Directions for including supporting documents:
1. This form should be attached to any documents submitted to the agenda.
2. Post Agenda Deadline items must be authorized by a Supervisor and the Policy Development Executive Director.
3. If necessary, provide original documents needing Board Chairperson signature to the Bureau Assistant prior to the start of a meeting.

From:	Sen.Nass
To:	Hereth, Daniel - DSPS; DSPS; DSPS Admin Rules
Cc:	Tierney, Michael - DSPS; Sen.Nass - LEGIS; Rep.Neylon - LEGIS; Grosz, Scott A - LEGIS; Kauffman, Jill - LEGIS; Duchek, Mike - LEGIS
Subject:	JCRAR Directive to Hold Preliminary Hearing on Scope Statement SS 055-25
Date:	Tuesday, August 26, 2025 3:14:38 PM

August 26, 2025

Doug Englebert, Chairperson
Controlled Substances Board
Department of Safety & Professional Services
P.O. Box 8366
Madison, WI 53708-8366

RE: SS 055-25 – Scheduling seven fentanyl-related substances

Dear Chairperson Englebert:

As co-chairperson of the Joint Committee for Review of Administrative Rules (JCRAR) and pursuant to s. 227.136 (1), Stats., I write to direct the Controlled Substances Board to hold a preliminary public hearing and comment period on Scope Statement SS 055-25, which was published in the Wisconsin Administrative Register on August 25, 2025.

Additionally, pursuant to s. 227.135 (2), Stats., please note that a scope statement may not be approved by the Secretary, the Department of Safety & Professional Services (DSPS), or any of the agencies under DSPS until after the preliminary public hearing and comment period is held by the agency, and accordingly, no activity may be conducted in connection with the drafting of a proposed rule until after such hearing and approval have occurred.

Please confirm receipt of this letter directing a preliminary hearing and comment period on the above scope statement.

Sincerely,

Steve Nass

Senator Steve Nass
Co-Chair, JCRAR

Cc: Dan Hereth, Secretary-designee, DSPS

STATEMENT OF SCOPE

CONTROLLED SUBSTANCES BOARD

Rule No.: CSB 2.012

Relating to: Scheduling Seven Fentanyl-Related Substances

Rule Type: Permanent

1. Finding/nature of emergency: N/A

2. Detailed description of the objective of the proposed rule:
The objective of the proposed rule is to schedule the following seven fentanyl-related substances as a schedule I controlled substance under s. 961.11 (4), Stats:

- Para-chlorofentanyl
- Ortho-chlorofentanyl
- Meta-fluorofuranyl fentanyl
- Ortho-methylcyclopropyl fentanyl
- Beta-methylacetyl fentanyl
- Tetrahydrothiofuranyl fentanyl
- Para-fluoro valeryl fentanyl

3. Description of the existing policies relevant to the rule, new policies proposed to be included in the rule, and an analysis of policy alternatives:
On December 30, 2024, the Department of Justice, Drug Enforcement Administration published its temporary scheduling order in the Federal Register adding the seven fentanyl-related substances listed above to schedule I of the federal Controlled Substances Act. The scheduling action was effective December 30, 2024.The Controlled Substances Board did not receive an objection to similarly adding the seven fentanyl-related substances listed above as schedule I controlled substances under ch. 961, Stats. within 30 days of the date of publication in the federal register of the final order listing the seven fentanyl-related substances listed about as schedule I controlled substances. Pursuant to s. 961.11(4), Stats., the Controlled Substances Board by affirmative action similarly treats the seven fentanyl-related substances listed above under chapter 961, Stats. by creating the following:

CSB 2.012 Addition of 7 Fentanyl Related Substances to Schedule I. **(1)** Section 961.14 (2) (nd) 8m, 12p, 16h, 16q, 16r, 17d, and 18m are created to read:

961.14 (2) (nd) 8m. Beta-methylacetyl fentanyl (N-phenyl-N-(1-(2-phenylpropyl)piperidin-4-yl)acetamide);

12p. Meta-fluorofuranyl fentanyl (N-(3-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)furan-2-carboxamide);

16h. Ortho-chlorofentanyl (N-(2-chlorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide);

16q. Ortho-methylcyclopropyl fentanyl (N-(2-methylphenyl)-N-(1-phenethylpiperidin-4-yl)cyclopropanecarboxamide);

16r. Para-chlorofentanyl (N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide;

17d. Para-fluoro valeryl fentanyl (N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)pentanamide);

18m. Tetrahydrothiofuranyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenyltetrahydrothiophen-2-carboxamide);

The Affirmative Action order, dated March 18, 2025, took effect on March 31, 2025, upon publication in the Administrative Register and expires upon promulgation of a final rule.

4. Detailed explanation of statutory authority for the rule:
Section 961.11 (1), Stats. provides that "[t]he controlled substances board shall administer this subchapter and may add substances to or delete or reschedule all substances listed in the schedules in ss. 961.14, 961.16, 961.18, 961.20 and 961.22 pursuant to the rule-making procedures of ch. 227."

Section 961.11(4), Stats. provides that "[i]f a substance is designated, rescheduled or deleted as a controlled substance under federal law and notice thereof is given to the controlled substances board, the board by affirmative action shall similarly treat the substance under this chapter after the expiration of 30 days from the date of publication in the federal register of a final order designating the substance as a controlled substance or rescheduling or deleting the substance or from the date of issuance of an order of temporary scheduling under 21 USC 811 (h), unless within that 30−day period, the board or an interested party objects to the treatment of the substance. If no objection is made, the board shall promulgate, without making the determinations or findings required by subs. (1), (1m), (1r) and (2) or s. 961.13, 961.15, 961.17, 961.19 or 961.21, a final rule, for which notice of proposed rulemaking is omitted, designating, rescheduling, temporarily scheduling or deleting the substance. If an objection is made the board shall publish notice of receipt of the objection and the reasons for objection and afford all interested parties an opportunity to be heard. At the conclusion of the hearing, the board shall make a determination with respect to the treatment of the substance as provided in subs. (1), (1m), (1r) and (2) and shall publish its decision, which shall be final unless altered by statute. Upon publication of an objection to the treatment by the board, action by the board under this chapter is stayed until the board promulgates a rule under sub. (2)."

5. Estimate of amount of time that state employees will spend developing the rule and of other resources necessary to develop the rule:
Approximately 80 hours.

6. List with description of all entities that may be affected by the proposed rule:
Law enforcement, district attorney offices, Dept of Justice, state courts and the Controlled Substances Board.

7. Summary and preliminary comparison with any existing or proposed federal regulation that is intended to address the activities to be regulated by the proposed rule:
On December 30, 2024, the Department of Justice, Drug Enforcement Administration published its temporary scheduling order in the Federal Register adding the seven fentanyl-related substances listed above to schedule I of the federal Controlled Substances Act. The scheduling action was effective December 30, 2024.

8. Anticipated economic impact of implementing the rule: None to minimal.

Contact Person: Nilajah Hardin, Administrative Rules Coordinator, DSPSAdminRules@wisconsin.gov

Approved for publication:

Douglas Englebert
Authorized Signature

07/15/2025
Date Submitted

Approved for implementation:

Authorized Signature

Date Submitted

State of Wisconsin
Department of Safety & Professional Services
AGENDA REQUEST FORM

1) Name and title of person submitting the request:	2) Date when request submitted:
Nilajah Hardin **Administrative Rules Coordinator**	**09/08/25** **Items will be considered late if submitted after 12:00 p.m. on the deadline date which is 8 business days before the meeting**

3) Name of Board, Committee, Council, Sections:

Controlled Substances Board

4) Meeting Date:	5) Attachments:	6) How should the item be titled on the agenda page?
09/19/25	☒ Yes ☐ No	**Administrative Rule Matters – Discussion and Consideration** 1. **Affirmative Action Order:** a. **CSB 2.013, Relating to Scheduling Dipentylone** b. **CSB 2.014, Relating to Scheduling 2 Synthetic Benzimidazole-Opioids** 2. **Final Rule Draft and Legislative Report** a. **CSB 2.011, Scheduling Ethylphenidate** 3. **Pending or Possible Rulemaking Projects** a. **Rule Projects Chart**

7) Place Item in:	8) Is an appearance before the Board being scheduled? *(If yes, please complete **Appearance Request** for Non-DSPS Staff)*	9) Name of Case Advisor(s), if required:
☒ Open Session ☐ Closed Session	☐ Yes ☒ No	**N/A**

10) Describe the issue and action that should be addressed:

Review and take action on Scope Statement, Preliminary Rules Drafts, and Final Rule Drafts.

Attachments:

- Affirmative Action Order – CSB 2.013 and 2.014
- Final Rule Draft, Legislative Report, EIA, Clearinghouse Report - CSB 2.011
- Rule Projects Chart

(All Board Rule Projects can be Viewed Here if Needed: https://dsps.wi.gov/Pages/RulesStatutes/PendingRules.aspx)

11) Authorization

Nilajah D. Hardin — 9/08/25

Signature of person making this request — **Date**

Supervisor (if required) — **Date**

Executive Director signature (indicates approval to add post agenda deadline item to agenda) — **Date**

Directions for including supporting documents:

1. **This form should be attached to any documents submitted to the agenda.**
2. **Post Agenda Deadline items must be authorized by a Supervisor and the Policy Development Executive Director.**
3. **If necessary, provide original documents needing Board Chairperson signature to the Bureau Assistant prior to the start of a meeting.**

STATE OF WISCONSIN
CONTROLLED SUBSTANCES BOARD

IN THE MATTER OF RULE-MAKING PROCEEDINGS BEFORE THE CONTROLLED SUBSTANCES BOARD	:	AFFIRMATIVE ACTION ORDER OF THE CONTROLLED SUBSTANCES BOARD

FINDINGS

1. On August 8, 2025, the Department of Justice, Drug Enforcement Administration published its final rule in the Federal Register listing Dipentylone in schedule I of the federal Controlled Substances Act. The rule was effective August 8, 2025.

2. The Controlled Substances Board did not receive an objection to similarly listing Dipentylone in schedule I under ch. 961, Stats. within 30 days of the date of publication in the federal register of the final order listing Dipentylone as a schedule I controlled substance.

3. The Controlled Substances Board will promulgate a final rule, without making the determinations or findings required by ss. 961.11(1), (1m), (1r) and (2) or s. 961.13 and omitting the notice of proposed rulemaking, listing Dipentylone as a schedule I controlled substance.

ORDER

Pursuant to s. 961.11(4), Stats., the Controlled Substances Board by affirmative action similarly treats Dipentylone under chapter 961, Stats. by creating the following:

CSB 2.013 Addition of Dipentylone to Schedule I. Section 961.14 (7) (L) 41., Stats., is created to read:

> **961.14 (7) (L) 41.** 1-(1,3-benzodioxol-5-yl)-2-(dimethylamino)pentan-1-one, commonly known as Dipentylone or N,N-dimethylpentylone.

This order shall become effective upon publication in the Administrative Register. The order expires upon promulgation of a final rule.

Dated _____

_____
Doug Englebert, Chairperson
Controlled Substances Board

STATE OF WISCONSIN
CONTROLLED SUBSTANCES BOARD

IN THE MATTER OF RULE-MAKING PROCEEDINGS BEFORE THE CONTROLLED SUBSTANCES BOARD	:	AFFIRMATIVE ACTION ORDER OF THE CONTROLLED SUBSTANCES BOARD

FINDINGS

1. On August 15, 2025, the Department of Justice, Drug Enforcement Administration published its temporary scheduling order in the Federal Register adding N-pyrrolidino metonitazene and N-pyrrolidino protonitazene to schedule I of the federal Controlled Substances Act. The scheduling action was effective August 15, 2025.

2. The Controlled Substances Board did not receive an objection to similarly listing N-pyrrolidino metonitazene and N-pyrrolidino protonitazene in schedule I under ch. 961, Stats. within 30 days of the date of publication in the federal register of the final order listing N-pyrrolidino metonitazene and N-pyrrolidino protonitazene as a schedule I controlled substances.

3. The Controlled Substances Board will promulgate a final rule, without making the determinations or findings required by ss. 961.11(1), (1m), (1r) and (2) or s. 961.13 and omitting the notice of proposed rulemaking, listing N-pyrrolidino metonitazene and N-pyrrolidino protonitazene as a schedule I controlled substances.

ORDER

Pursuant to s. 961.11(4), Stats., the Controlled Substances Board by affirmative action similarly treats N-pyrrolidino metonitazene and N-pyrrolidino protonitazene under chapter 961, Stats. by creating the following:

CSB 2.014 Addition of 2 Synthetic Benzimidazole-Opioids to Schedule I. Section 961.14 (2) (xm) 8e. and 8m., Stats., are created to read:

961.14 (2) (xm) 8e. N-pyrrolidino metonitazene also known as metonitazepyne (2-(4-methyoxbenzyl)-5-nitro-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzimidazole).

961.14 (2) (xm) 8m. and N-pyrrolidino protonitazene also known as protonitazepyne (5-nitro-2-(4-propoxybenzyl)-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzimidazole).

This order shall become effective upon publication in the Administrative Register and expires upon promulgation of a final rule.

Dated _____

_____
Doug Englebert, Chair
Controlled Substances Board

STATE OF WISCONSIN
CONTROLLED SUBSTANCES BOARD

IN THE MATTER OF RULEMAKING	**:**	
PROCEEDINGS BEFORE THE	**:**	**REPORT TO THE LEGISLATURE**
CONTROLLED SUBSTANCES BOARD	**:**	**CR 25-060**

I. THE PROPOSED RULE: The proposed rule, including the analysis and text, is attached.

II. REFERENCE TO APPLICABLE FORMS: N/A

III. FISCAL ESTIMATE AND EIA: The Fiscal Estimate and EIA is attached.

IV. DETAILED STATEMENT EXPLAINING THE BASIS AND PURPOSE OF THE PROPOSED RULE, INCLUDING HOW THE PROPOSED RULE ADVANCES RELEVANT STATUTORY GOALS OR PURPOSES:

This rule schedules Ethylphenidate as a schedule I controlled substance. The Controlled Substances Board will promulgate a final rule, without making the determinations or findings required by ss. 961.11(1), (1m), (1r) and (2) or s. 961.19 and omitting the notice of proposed rulemaking, listing Ethylphenidate as a schedule I controlled substance. Pursuant to s. 961.11(4), Stats., the Controlled Substances Board by affirmative action similarly treats Ethylphenidate under chapter 961, Stats. by creating the following:

> **CSB 2.011 Addition of Ethylphenidate to Schedule I**. . Section 961.14 (7) (u), Stats., is created to read:
>
> > **961.14 (7) (u)** Ethyl 2-phenyl-2-(piperidin-2-yl)acetate, commonly known as Ethylphenidate.

The Affirmative Action order, dated November 27, 2024, took effect on December 16, 2024, upon publication in the Administrative Register and expires upon promulgation of a final rule.

V. SUMMARY OF PUBLIC COMMENTS AND THE BOARD'S RESPONSES, EXPLANATION OF MODIFICATIONS TO PROPOSED RULES PROMPTED BY PUBLIC COMMENTS:

Per s. 961.11(4), Stats., if no objection is made, the board shall promulgate a final rule for which notice of proposed rulemaking is omitted. Therefore, the Board did not hold a public hearing. No other public comments were received.

VI. RESPONSE TO LEGISLATIVE COUNCIL STAFF RECOMMENDATIONS: Legislative Council Staff did not make any recommendations.

VII. REPORT FROM THE SBRRB AND FINAL REGULATORY FLEXIBILITY ANALYSIS: N/A

STATE OF WISCONSIN
CONTROLLED SUBSTANCES BOARD

IN THE MATTER OF RULE-MAKING PROCEEDINGS BEFORE THE CONTROLLED SUBSTANCES BOARD	:	PROPOSED ORDER OF THE CONTROLLED SUBSTANCES BOARD ADOPTING RULES (CLEARINGHOUSE RULE 25-060)

PROPOSED ORDER

An order of the Controlled Substances Board to create CSB 2.011, relating to scheduling Ethylphenidate.

Analysis prepared by the Department of Safety and Professional Services.

ANALYSIS

Statutes interpreted: s. 961.14, Stats.

Statutory authority: s. 961.11 (1) and (4), Stats.

Explanation of agency authority:
Section 961.11 (1), Stats. provides that "[t]he controlled substances board shall administer this subchapter and may add substances to or delete or reschedule all substances listed in the schedules in ss. 961.14, 961.16, 961.18, 961.20 and 961.22 pursuant to the rule-making procedures of ch. 227."

Section 961.11(4), Stats. provides that "[i]f a substance is designated, rescheduled or deleted as a controlled substance under federal law and notice thereof is given to the controlled substances board, the board by affirmative action shall similarly treat the substance under this chapter after the expiration of 30 days from the date of publication in the federal register of a final order designating the substance as a controlled substance or rescheduling or deleting the substance or from the date of issuance of an order of temporary scheduling under 21 USC 811 (h), unless within that 30−day period, the board or an interested party objects to the treatment of the substance. If no objection is made, the board shall promulgate, without making the determinations or findings required by subs. (1), (1m), (1r) and (2) or s. 961.13, 961.15, 961.17, 961.19 or 961.21, a final rule, for which notice of proposed rulemaking is omitted, designating, rescheduling, temporarily scheduling or deleting the substance. If an objection is made the board shall publish notice of receipt of the objection and the reasons for objection and afford all interested parties an opportunity to be heard. At the conclusion of the hearing, the board shall make a determination with respect to the treatment of the substance as provided in subs. (1), (1m), (1r) and (2) and shall publish its decision, which shall be final unless altered by statute. Upon publication of an objection to the treatment by the board, action by the board under this chapter is stayed until the board promulgates a rule under sub. (2)."

Related statute or rule: s. 961.14, Stats.

Summary of, and comparison with, existing or proposed federal regulation:
On October 22, 2024, the Department of Justice, Drug Enforcement Administration published its final rule in the Federal Register adding Ethylphenidate to schedule I of the federal Controlled Substances Act. The scheduling action was effective November 21, 2024.

Plain language analysis:
This rule schedules Ethylphenidate as a schedule I controlled substance. The Controlled Substances Board will promulgate a final rule, without making the determinations or findings required by ss. 961.11(1), (1m), (1r) and (2) or s. 961.19 and omitting the notice of proposed rulemaking, listing Ethylphenidate as a schedule I controlled substance. Pursuant to s. 961.11(4), Stats., the Controlled Substances Board by affirmative action similarly treats Ethylphenidate under chapter 961, Stats. by creating the following:

> **CSB 2.011 Addition of Ethylphenidate to Schedule I**. . Section 961.14 (7) (u), Stats., is created to read:
>
> > **961.14 (7) (u)** Ethyl 2-phenyl-2-(piperidin-2-yl)acetate, commonly known as Ethylphenidate.

The Affirmative Action order, dated November 27, 2024, took effect on December 16, 2024, upon publication in the Administrative Register and expires upon promulgation of a final rule.

Summary of public comments received on statement of scope and a description of how and to what extent those comments and feedback were taken into account in drafting the proposed rule: The Controlled Substances Board held a Preliminary Hearing on Statement of Scope for this project on May 9, 2025. No comments were received.

Comparison with rules in adjacent states:
Illinois: Illinois has not listed Ethylphenidate as a schedule I controlled substance [720 Illinois Compiled Statutes 570 Section 204].

Iowa: Iowa has not listed Ethylphenidate as a schedule I controlled substance [Iowa Code 124.204].

Michigan: Michigan has not listed Ethylphenidate as a schedule I controlled substance [Michigan Compiled Laws s. 333.7212].

Minnesota: Minnesota has not listed Ethylphenidate as a schedule I controlled substance [Minnesota Statutes 152.02 (2)].

Summary of factual data and analytical methodologies:
The methodology was to schedule Ethylphenidate to conform with the federal Controlled Substances Act.

Analysis and supporting documents used to determine effect on small business or in preparation of economic impact analysis:

The proposed rule was posted for a period of 14 days to solicit public comment on economic impact, including how the proposed rules may affect businesses, local government units, and individuals. No comments were received.

Fiscal Estimate and Economic Impact Analysis:
The fiscal estimate and economic impact analysis is attached.

Effect on small business:
These proposed rules do not have an economic impact on small businesses, as defined in s. 227.114 (1), Stats. The Department's Regulatory Review Coordinator may be contacted by email at Jennifer.Garrett@wisconsin.gov, or by calling (608) 266-2112.

Agency contact person:
Nilajah Hardin, Administrative Rules Coordinator, Department of Safety and Professional Services, Division of Policy Development, 4822 Madison Yards Way, P.O. Box 8366, Madison, Wisconsin 53708; email at DSPSAdminRules@wisconsin.gov.

TEXT OF RULE

SECTION 1. CSB 2.011 is created to read:

CSB 2.011 Addition of Ethylphenidate to Schedule I. . Section 961.14 (7) (u), Stats., is created to read:

> **961.14 (7) (u)** Ethyl 2-phenyl-2-(piperidin-2-yl)acetate, commonly known as Ethylphenidate.

SECTION 2. EFFECTIVE DATE. The rules adopted in this order shall take effect on the first day of the month following publication in the Wisconsin Administrative Register, pursuant to s. 227.22 (2) (intro.), Stats.

(END OF TEXT OF RULE)

This Proposed Order of the Controlled Substances Board is approved for submission to the Governor and Legislature.

Dated _____ Agency _____

Chairperson
Controlled Substances Board

STATE OF WISCONSIN
DEPARTMENT OF ADMINISTRATION
DOA-2049 (R09/2016)

DIVISION OF EXECUTIVE BUDGET AND FINANCE
101 EAST WILSON STREET, 10TH FLOOR
P.O. BOX 7864
MADISON, WI 53707-7864
FAX: (608) 267-0372

ADMINISTRATIVE RULES
Fiscal Estimate & Economic Impact Analysis

1. Type of Estimate and Analysis
☒ Original ☐ Updated ☐ Corrected

2. Date
08/12/25

3. Administrative Rule Chapter, Title and Number (and Clearinghouse Number if applicable)
CSB 2.011

4. Subject
Scheduling Ethylphenidate

5. Fund Sources Affected
☐ GPR ☐ FED ☒ PRO ☐ PRS ☐ SEG ☐ SEG-S

6. Chapter 20, Stats. Appropriations Affected
s. 20.165 (1) (g) (hg)

7. Fiscal Effect of Implementing the Rule
☐ No Fiscal Effect ☐ Increase Existing Revenues ☒ Increase Costs ☐ Decrease Costs
☐ Indeterminate ☐ Decrease Existing Revenues ☐ Could Absorb Within Agency's Budget

8. The Rule Will Impact the Following (Check All That Apply)
☐ State's Economy
☐ Local Government Units
☐ Specific Businesses/Sectors
☐ Public Utility Rate Payers
☐ Small Businesses **(if checked, complete Attachment A)**

9. Estimate of Implementation and Compliance to Businesses, Local Governmental Units and Individuals, per s. 227.137(3)(b)(1).
$0

10. Would Implementation and Compliance Costs Businesses, Local Governmental Units and Individuals Be $10 Million or more Over Any 2-year Period, per s. 227.137(3)(b)(2)?
☐ Yes ☒ No

11. Policy Problem Addressed by the Rule
This rule schedules Ethylphenidate as a schedule I controlled substance. The Controlled Substances Board will promulgate a final rule, without making the determinations or findings required by ss. 961.11(1), (1m), (1r) and (2) or s. 961.19 and omitting the notice of proposed rulemaking, listing Ethylphenidate as a schedule I controlled substance. The Affirmative Action order, dated November 27, 2024, took effect on December 16, 2024, upon publication in the Administrative Register and expires upon promulgation of a final rule.

12. Summary of the Businesses, Business Sectors, Associations Representing Business, Local Governmental Units, and Individuals that may be Affected by the Proposed Rule that were Contacted for Comments.
The proposed rule will be for a period of 14 days to solicit public comment on economic impact, including how the proposed rules may affect businesses, local government units, and individuals.

13. Identify the Local Governmental Units that Participated in the Development of this EIA.
None.

14. Summary of Rule's Economic and Fiscal Impact on Specific Businesses, Business Sectors, Public Utility Rate Payers, Local Governmental Units and the State's Economy as a Whole (Include Implementation and Compliance Costs Expected to be Incurred)
DSPS estimates a total of $3000.00 in one-time staffing costs to implement the rule. The estimated need for 0.1 limited term employee (LTE) is for rule drafting, legal review, as well as updating website and forms. The one-time estimated costs cannot be absorbed in the currently appropriated agency budget.

15. Benefits of Implementing the Rule and Alternative(s) to Implementing the Rule
The benefit is that the federal and state controlled substances acts will be uniform to avoid stakeholder confusion.

16. Long Range Implications of Implementing the Rule
The long range implications of implementing the rule are that Ethylphenidate will be added to Wis. Stat. ch. 961 as a schedule I controlled substance.

17. Compare With Approaches Being Used by Federal Government

STATE OF WISCONSIN
DEPARTMENT OF ADMINISTRATION
DOA-2049 (R09/2016)

DIVISION OF EXECUTIVE BUDGET AND FINANCE
101 EAST WILSON STREET, 10TH FLOOR
P.O. BOX 7864
MADISON, WI 53707-7864
FAX: (608) 267-0372

ADMINISTRATIVE RULES
Fiscal Estimate & Economic Impact Analysis

On October 22, 2024, the Department of Justice, Drug Enforcement Administration published its final rule in the Federal Register adding Ethylphenidate to schedule I of the federal Controlled Substances Act. The scheduling action was effective November 21, 2024.

18. Compare With Approaches Being Used by Neighboring States (Illinois, Iowa, Michigan and Minnesota)

Illinois: Illinois has not listed Ethylphenidate as a schedule I controlled substance [720 Illinois Compiled Statutes 570 Section 204].

Iowa: Iowa has not listed Ethylphenidate as a schedule I controlled substance [Iowa Code 124.204].

Michigan: Michigan has not listed Ethylphenidate as a schedule I controlled substance [Michigan Compiled Laws s. 333.7212].

Minnesota: Minnesota has not listed Ethylphenidate as a schedule I controlled substance [Minnesota Statutes 152.02 (2)].

19. Contact Name	20. Contact Phone Number
Nilajah Hardin, Administrative Rules Coordinator	608-267-7139

This document can be made available in alternate formats to individuals with disabilities upon request.

STATE OF WISCONSIN
DEPARTMENT OF ADMINISTRATION
DOA-2049 (R09/2016)

DIVISION OF EXECUTIVE BUDGET AND FINANCE
101 EAST WILSON STREET, 10TH FLOOR
P.O. BOX 7864
MADISON, WI 53707-7864
FAX: (608) 267-0372

ADMINISTRATIVE RULES
Fiscal Estimate & Economic Impact Analysis

ATTACHMENT A

1. Summary of Rule's Economic and Fiscal Impact on Small Businesses (Separately for each Small Business Sector, Include Implementation and Compliance Costs Expected to be Incurred)

2. Summary of the data sources used to measure the Rule's impact on Small Businesses

3. Did the agency consider the following methods to reduce the impact of the Rule on Small Businesses?
☐ Less Stringent Compliance or Reporting Requirements
☐ Less Stringent Schedules or Deadlines for Compliance or Reporting
☐ Consolidation or Simplification of Reporting Requirements
☐ Establishment of performance standards in lieu of Design or Operational Standards
☐ Exemption of Small Businesses from some or all requirements
☐ Other, describe:

4. Describe the methods incorporated into the Rule that will reduce its impact on Small Businesses

5. Describe the Rule's Enforcement Provisions

6. Did the Agency prepare a Cost Benefit Analysis (if Yes, attach to form)
☐ Yes ☐ No

LCRC
FORM 2

Wisconsin Legislative Council

RULES CLEARINGHOUSE

Scott Grosz
Clearinghouse Director

Anne Sappenfield
Legislative Council Director

Margit Kelley
Clearinghouse Assistant Director

CLEARINGHOUSE REPORT TO AGENCY

[THIS REPORT HAS BEEN PREPARED PURSUANT TO S. 227.15, STATS. THIS IS A REPORT ON A RULE AS ORIGINALLY PROPOSED BY THE AGENCY; THE REPORT MAY NOT REFLECT THE FINAL CONTENT OF THE RULE IN FINAL DRAFT FORM AS IT WILL BE SUBMITTED TO THE LEGISLATURE. THIS REPORT CONSTITUTES A REVIEW OF, BUT NOT APPROVAL OR DISAPPROVAL OF, THE SUBSTANTIVE CONTENT AND TECHNICAL ACCURACY OF THE RULE.]

CLEARINGHOUSE RULE **25-060**

AN ORDER to create CSB 2.011, relating to scheduling ethylphenidate.

Submitted by **CONTROLLED SUBSTANCES BOARD**

08-12-2025 RECEIVED BY LEGISLATIVE COUNCIL.
08-29-2025 REPORT SENT TO AGENCY.

MSK:KAM

LEGISLATIVE COUNCIL RULES CLEARINGHOUSE REPORT

This rule has been reviewed by the Rules Clearinghouse. Based on that review, comments are reported as noted below:

1. STATUTORY AUTHORITY [s. 227.15 (2) (a)]

   Comment Attached YES ☐ NO ☑

2. FORM, STYLE AND PLACEMENT IN ADMINISTRATIVE CODE [s. 227.15 (2) (c)]

   Comment Attached YES ☐ NO ☑

3. CONFLICT WITH OR DUPLICATION OF EXISTING RULES [s. 227.15 (2) (d)]

   Comment Attached YES ☐ NO ☑

4. ADEQUACY OF REFERENCES TO RELATED STATUTES, RULES AND FORMS [s. 227.15 (2) (e)]

   Comment Attached YES ☐ NO ☑

5. CLARITY, GRAMMAR, PUNCTUATION AND USE OF PLAIN LANGUAGE [s. 227.15 (2) (f)]

   Comment Attached YES ☐ NO ☑

6. POTENTIAL CONFLICTS WITH, AND COMPARABILITY TO, RELATED FEDERAL REGULATIONS [s. 227.15 (2) (g)]

   Comment Attached YES ☐ NO ☑

7. COMPLIANCE WITH PERMIT ACTION DEADLINE REQUIREMENTS [s. 227.15 (2) (h)]

   Comment Attached YES ☐ NO ☑

Controlled Substances Board
Rule Projects (updated 09/08/25)

CH Rule Number	Scope Number	Scope Expiration Date	Code Chapter Affected	Relating Clause	Stage of Rule Process	Next Step
24-083	086-24	02/05/2027	CSB 2.006	Scheduling 5 Synthetic Cannabinoids	Effective 09/01/25	N/A
24-084	087-24	02/05/2027	CSB 2.007	Scheduling ADB-BUTINANCA, α-PiHP, and 3- MMC	Effective 09/01/25	N/A
24-085	088-24	02/05/2027	CSB 2.008	Scheduling 2-methyl AP-237	Effective 09/01/25	N/A
25-021	113-24	06/02/2027	CSB 2.009	Scheduling 2 Synthetic Benzimidazole-Opioids	Effective 10/01/25	N/A
25-060	016-25	09/10/2027	CSB 2.010 (Renumbered to 2.011)	Scheduling Ethylphenidate	Final Rule Draft reviewed at 09/19/25 Meeting	Submission to Governor's Office for Approval and Notification to Legislature
Not Assigned Yet	055-25	02/25/2028	CSB 2.011 (Renumbered to 2.012)	Scheduling 7 Fentanyl-related Substances	Preliminary Hearing on Statement of Scope held at 09/19/25 meeting	Scope Implementation
Not Assigned Yet	Not Assigned Yet	Not Assigned Yet	CSB 2.013	Scheduling Dipentylone	Affirmative Action Order reviewed at 09/19/25 Meeting	Affirmative Action Order Submission for Publication and Drafting of Scope Statement
Not Assigned Yet	Not Assigned Yet	Not Assigned Yet	CSB 2.014	Scheduling 2 Synthetic Benzimidazole-Opioids	Affirmative Action Order reviewed at 09/19/25 Meeting	Affirmative Action Order Submission for Publication and Drafting of Scope Stement

State of Wisconsin
Department of Safety & Professional Services

AGENDA REQUEST FORM

1) Name and title of person submitting the request:	2) Date when request submitted:
Marjorie Liu Program Lead, PDMP	0909/2025 Items will be considered late if submitted after 12:00 p.m. on the deadline date which is 8 business days before the meeting

3) Name of Board, Committee, Council, Sections:

Controlled Substances Board

4) Meeting Date:	5) Attachments:	6) How should the item be titled on the agenda page?
0919/2025	☒ Yes ☐ No	Prescription Drug Monitoring Program (PDMP) Updates – Discussion and Consideration

7) Place Item in:	8) Is an appearance before the Board being scheduled? *(If yes, please complete **Appearance Request** for Non-DSPS Staff)*	9) Name of Case Advisor(s), if required:
☒ Open Session ☐ Closed Session	☐ Yes ☒ No	

10) Describe the issue and action that should be addressed:

1. WI ePDMP Operations
    a. Recent and Upcoming Releases
    b. EHR Integration Status
2. WI PDMP Outreach

11) Authorization

Marjorie Liu — September 9, 2025

Signature of person making this request — **Date**

Supervisor (if required) — **Date**

Executive Director signature (indicates approval to add post agenda deadline item to agenda) — **Date**

Directions for including supporting documents:
1. This form should be attached to any documents submitted to the agenda.
2. Post Agenda Deadline items must be authorized by a Supervisor and the Policy Development Executive Director.
3. If necessary, provide original documents needing Board Chairperson signature to the Bureau Assistant prior to the start of a meeting.

2023-2025 Development and Release Summary

Updated 09.05.2025

Release Date	Description
R33.22 **August 2025**	**DEA -> NPI Systemic Changeover** • NPI information auto-populated on the Record Entry screen for Pharmacy and Dispensing Practitioner account types • Erroneously flagged errors of historical records removed from pharmacy error logs **Administration** Dispenser Report workflow fixes for Law Enforcement or Government user
R33.21 **July 2025**	**DEA -> NPI Systemic Changeover** • Dispenser Compliance Report reverted to using DEA first, switching to NPI on 12/1 • Pharmacy Zero Report auto populates NPI or leaves blank if account profile doesn't Include NPI • Data Submitter Guide updates **Administration** Fixes for Detailed Prescriber Monitoring Report **User Interface** • Dispenser Report download fixes for Law Enforcement or Government user • Submission data field PHA05 (Pharmacy Address 1) now accepts up to 55 characters
R33.20 **June 2025**	**Website changes adapting to NPI Requirements** Automated Notification Language Updates: • Submission compliance notification when NPI is missing • Gabapentin reporting guideline updates User Portal • Healthcare Professional Account – NPI requirement pop up updates • Law enforcement/investigative unit account: NPI added to prescriber and dispenser report request screen for Data Analytics • Metrics calculations revert to DEA-based
R33.19 **May 2025**	**Website changes adapting to NPI Requirements** Data Analytics • NPI Search Added to Detailed Prescriber Monitoring Report • NPI Added to Opioid Prescribing Practice Summary Report

	Admin Portal Fixes and Updates
R33.18 **April 2025**	Website Administration: • On-going Formatting and Calculation cleanups for automated Reports • NPI data field added to reports User Portal: NPI field added to search screen (for law enforcement, prosecutorial, and regulatory agencies)
R33.17 **March 2025**	User Portal: • Additional DEA fields in Prescribers account profile • NPI field added in Pharmacy account profile
R33.16 **February 2025**	Data Analytics Updates: • MME Conversion Factors updates • Buprenorphine exclusion rules applied to automated reporting of prescribing reports User Interface Updates • Healthcare Professionals - MME Calculator & Addiction Resource Updates • Investigators - Dispenser Report Request via User Accounts Administrative workflow updates - NPI added to Pending Account Registration Review Webpage Language Updates: Registration Page, Dashboard charts
R33.15.1 **February 2025**	Emergency Release to fix errors for out of state queries connecting via PMPi hub
R33.15 **January 2025**	Data Analytics Updates: • New admin tool of adding additional DEA numbers to automate Detailed Prescriber Monitoring Report • Formatting updates on Opioid Practice Summary Report User Interface Updates: • Pharmacy Account data revise/edit screen now with multiple DEAs dropdown selection
R33.14 **January 2025**	Updates to online form “Report Suspected Errors in WI ePDMP Date” PDF Pharmacy additional DEA display Increased License Number Character Limits from 7 to 8 File Processing Updates - Skipping Duplicate Files
R33.13 **December 2024**	User Interface: • Updated Text on the Delegate Management Screen • Updated Calculations for Daily Prescribing Volume Ranking for Opioids • License Number is no Longer a Required Field for a Medical Coordinator Account Admin Portal Updates: • Added Submission Date to Prescriber Alerts Table • NDC of Dispensed Medications displayed in the prescriber Report • Updated the Prescriber Query Compliance Report

R33.12 **November 2024**	ePDMP Webpage Updates: Contact Us info & user registration screen for Medical Coordinator and Researcher Analytics and Reports Updates- • Prescriber Monitoring Report Charts Readability • Prescriber Address populated on Dispensing History Details Administrative Workflow Enhancement: Alert reviewing screen updates
R33.11 **September 2024**	Non – HCP Alert Displays on Requested Reports Detailed Prescriber Monitoring Report Rework Updated Quarterly CSB Reports Prescriber Address Visible on Patient Report Table
R33.10 **August 2024**	Automation of Reports: • Opioid Prescribing Practice Summary Report Review • Quarterly Statistics for CSB Report Review • Detailed Prescriber Monitoring Report Review • Prescriber Address Populated on UI EHR Support Partial Refill Review
R33.9 **July 2024**	Opioid Prescribing Practice Summary Report Review Text Updates in UI Updates to notification emails Prescriber Query Compliance Report update
R33.8 **June 2024**	Opioid Prescribing Practice Summary Report Review Quarterly CSB Report Review Compound Drug UI Statistic utilization optimizations Addition of email address to non-HCP query requests
R33.7 **May 2024**	Dispenser Compliance Report Review Submitter/Dispenser Report Review
R33.6 **April 2024**	System Updates • Pending Account Changes UI language • UAT email notification links • Controlled Substance UI language Updated error messages for Submitters RXCheck 3.1 Update and Patch Statistics Dashboard populate counties' logic EHR Support
R33.5 **March 2024**	Statistics reporting updates EHR/Epic OAuth Support File Submission Queue processing

R33.4 **February 2024**	DEA File Updates LicenseE Update – State License Validation Training Materials Update File Processing support EHR support
R33.3 **January 2024**	LicenseE Update – New User Registration LicenseE Update – User Login Validation PDMP UI Page Text Updates • Home Page • Contact Us • Patient History Detail File Processing Support EHR Support
R33.2 **January 2024**	Pharmacy Users fixes • Zero reports • Revise/Correct/Void File Processing support EHR support
R33.1 **November 2023**	Utilization page updates PMPi States Admin Manage Alerts Timeout Patient Matching Updates
R33.0 **November 2023**	Geocoding Address2 Line rejection Updated Submitter Guide
R32.5 **October 2023**	File processing support
R32.4 **October 2023**	EHR Support
R32.3 **October 2023**	EHR Support
R32.2 **October 2023**	EHR Support

R32.1 **October 2023**	Iframe support Epic
R32 **October 2023**	**HRG 2020 Grant Release**

WI ePDMP Integration Services Summary

Updated 09.05.2025

Pending Health Systems and EHR Platforms	Status			Notes
Internal Medicine Associates	In discussion			
MECFS Clinic MN	In discussion			
Oak Leaf	In discussion			
CareATC	In discussion			
Connected Health Systems (61% of monthly patient queries)	**Free Pricing Model**	**Implementation Date**	**Est. Total # of Users**	**Notes**
Advent Health		03/05/2023	15	
Allina Health	Y	09/18/2023	100	
Ascension Wisconsin				
Aspirus Health Care				
Aurora Health Care	Y	05/08/2024	12,000	
Children's Hospital of Wisconsin	Y	09/01/2022	300	
Clark County	Y	11/01/2023		
Clean Slate	Y	09/01/2022	26	
CompuGroup Medical	Y	08/14/2024	50	
DrFirst	**Y**	05/01/2025		
Froedtert & the Medical College of Wisconsin			100	Pending signed Free agreement
GHC of South Central Wisconsin	Y	09/01/2024		
Gundersen Health System			800	Pending signed Free agreement
HealthPartners				
HSHS / Prevea Health	Y	01/01/2023	500	
M Health Fairview	Y	08/01/2022	30	
Marshfield Clinic	Y	09/01/2022	100	
Mayo Clinic				
Mercy Health	Y	08/01/2022	766	
Monroe Clinic				

NOVO Health Technology Group	Y	02/01/2023		
Ochin	Y	12/21/2022	100	
ProHealth Care	Y	1/17/2025		
QuadMed, LLC	Y	5/17/2023	40	
SSM Health				
Thedacare				Pending signed Free agreement
UnityPoint				
UW Health			4000	
Wisconsin Statewide Health Information Network	Y	09/01/2022	3500	

DrFirst Facilities	
Alay Health Team	National Medical Groups
Associated Mental Health Consultants	Nova Integrated Care LLC
Behavioral Health Svcs of Racine Co.	Oak Medical
Benjamin S. Gozon MDSC D/B/A Capitol Rehabilitation Clinic	Oral Surgery Associates of Milwaukee
Christian Family Solutions	Orthopedic Hospital of Wisconsin
Door County Memorial Hospital	Pain Management and Treatment Center
Dr. Colleen Worth, DNP, APNP	Pediatrics Associates
Empower Recovery	Reka Furedi MD
Envision ADHD Clinic	Red Oak Counseling
FAMILY PSYCHIATRIC CARE, LLC	Regional Medical Center
Fort Healthcare	Richland Hospital
GI Associates LLC	Rogers Memorial Hospital
Heartland Hospice	Sauk Prairie Memorial Hospital
Jonathan Hoerl PMHNP	Shorewood Behavioral Health
Kelly Pickens	Third Eye Health
Lake Superior Community Health Center	University of Wisconsin - Milwaukee
Linc Health Clinic	Watertown Rainbow Hospice
Lifestance Health WI	Wauwatosa Children’s Clinic
Madison Recovery Center	Watertown Regional Medical Center

Marshfield Clinic Health System	Yee Xiong MD
Mental Health Specialty Group PA	
Mile Bluff Medical Center	
Milwaukee Medical Associate, SC	
Mindful Healing and Wellness LLC	

2025 WI PDMP Outreach Calendar

MONTH	EVENT	DESCRIPTION	DATES	NOTES
January	Overdose Fatality Review (OFR) State Advisory Group	DSPS Representative; inter-agency advisory board for OFR participating local sites	1/9/2025	Virtual; Quarterly Meeting
February				
March	Bi-Annual RxCheck Governance Board Meeting	Board Member-Participant; Interstate PDMP data exchange discussion	3/18-3/19/2025	San Diego, CA
April	Overdose Fatality Review (OFR) Local Community Meeting	PDMP Presentation; Portage County OFR Team Meeting	4/1/2025	Virtual
	Overdose Fatality Review (OFR) State Advisory Group	DSPS Representative; inter-agency advisory board for OFR participating local sites	4/10/2025	Virtual; Quarterly Meeting
May	Opioids, Stimulants, and Trauma Summit	Information Booth	5/6-5/8/2025	Wisconsin Dells
June	PMP InterConnect Steering Committee Meeting	Participant; Annual national meeting for PDMP administrators organized by National Association of Boards of Pharmacy (NABP)	6/23-6/24/2025	Mount Prospect, IL
July	Overdose Fatality Review (OFR) State Advisory Group	DSPS Representative; inter-agency advisory board for OFR participating local sites	7/10/2025	Virtual; Quarterly Meeting
August				
September	BadgerTraCS-PDMP Integration Outreach	Collaborative project across DOJ, DOT, & DSPS on promoting entry of law enforcement alerts	On-going	
October	Overdose Fatality Review (OFR) State Advisory Group	DSPS Representative; inter-agency advisory board for OFR participating local sites	10/9/2025	Virtual; Quarterly Meeting
	NASCSA Conference (National Association of State Controlled Substances Authorities)	Participant; annual national meeting organized by NASCSA for government controlled substances authority, PDMP and healthcare professionals	10/20-10/23/2025	New Orleans, LA
November				
December	Bi-Annual RxCheck Governance Board Meeting	Board Member-Participant; Interstate PDMP data exchange discussion	TBD	TBD